15-PGDH and muscle loss on GLP-1 drugs

A study published in the Proceedings of the National Academy of Sciences (PNAS) on 2 June 2026 reports that blocking the enzyme 15-PGDH restored muscle repair and grip strength in obese mice treated with semaglutide^[1]. The finding matters because muscle loss is a recognised side effect of rapid weight loss on GLP-1 receptor agonists, and no approved therapy currently addresses it.

What 15-PGDH does and why it matters here

15-PGDH (15-hydroxyprostaglandin dehydrogenase) is an enzyme that breaks down prostaglandin E2 (PGE2), a signalling molecule involved in tissue repair. In 2021, the same Stanford lab, led by Helen Blau, showed that 15-PGDH levels rise in aged muscle and that inhibiting the enzyme with a small molecule called SW033291 restored muscle mass and strength in old mice^[2]. The new study extends that work to a different kind of muscle loss: the kind caused by GLP-1 receptor agonist therapy during weight reduction.

How the experiment worked

Researchers fed mice a high-fat diet to induce obesity, then treated them with semaglutide alone or semaglutide plus a 15-PGDH inhibitor. After the drug regimen, they injured the animals' muscles and measured how well the tissue regenerated. Mice on semaglutide alone lost significant muscle mass and showed impaired repair after injury. Mice that received both semaglutide and the 15-PGDH inhibitor maintained the full weight-loss benefit of semaglutide while showing improved myofiber size, better muscle stem cell function, and stronger grip strength after injury^[1].

The combination did not compromise fat loss. The weight reduction was comparable between the semaglutide-only and combination groups, meaning the 15-PGDH inhibitor selectively protected muscle without blunting the metabolic effects of the GLP-1 receptor agonist^[1]. The mechanism, according to the authors, works through boosting prostaglandin E2 levels, which in turn stimulates muscle stem cell (satellite cell) activation and promotes myofiber growth after injury.

What the study does not show

This is a mouse study. No human has received a 15-PGDH inhibitor alongside semaglutide or any other GLP-1 receptor agonist. The inhibitor used (SW033291) is a research tool compound, not a drug candidate in clinical trials. No pharmaceutical company has publicly disclosed plans to develop a 15-PGDH inhibitor for this use. The muscle injury model (cardiotoxin injection into the tibialis anterior) is a standard preclinical assay, but it does not directly replicate the gradual muscle wasting that patients experience during months of GLP-1-driven weight loss. The study also did not include female mice, and sex differences in muscle biology and GLP-1 response are well documented.

The authors themselves frame the result as proof of concept: blocking a single prostaglandin-degrading enzyme can synergise with GLP-1 therapy to protect skeletal muscle. Translating that into a human co-therapy is a separate, longer process.

Why muscle loss during GLP-1 therapy is a growing concern

Weight lost on GLP-1 receptor agonists is not all fat. Clinical trials of semaglutide and tirzepatide consistently report that roughly a quarter to a third of total weight lost is lean mass, primarily skeletal muscle. In STEP-1, for example, participants on semaglutide 2.4 mg lost an average of 14.9% body weight at 68 weeks, and body-composition substudy data showed meaningful lean-mass decline alongside the fat reduction. For younger, otherwise healthy patients that may be tolerable. For older adults or those already at risk of sarcopenia (age-related muscle wasting), the trade-off is less straightforward, and the question of how to preserve strength while losing fat is clinically urgent. Several research groups are now testing co-interventions, including resistance exercise, higher protein intake, and myostatin inhibitors such as bimagrumab, to see whether the lean-mass loss can be reduced without sacrificing fat reduction.

Where this fits for readers following the GLP-1 space

The 15-PGDH pathway is one of several strategies under investigation. It is the earliest-stage of those strategies: preclinical, single-lab, no human data. But the underlying biology, boosting PGE2 to support muscle stem cells, is well characterised from Blau's earlier ageing work^[2], and the question it addresses (how to keep muscle while losing fat on an incretin drug) is one of the most-asked in the field right now.

If you are on a GLP-1 receptor agonist and concerned about muscle loss, the evidence-based steps today remain resistance training and adequate protein intake. No pharmacological add-on for muscle preservation during GLP-1 therapy has been tested in humans at scale. That may change, but it has not changed yet. See our semaglutide page for a full overview of what the clinical evidence shows, and talk to your prescriber about a plan that includes exercise.